Local control rate, survival and toxicity of organ-sparing radiation of muscle-invasive bladder cancer: A contemporary series of 248 patients

by N. Verschoor, W.D. Heemsbergen, J.L. Boormans, M. Franckena
Published 2020-07-01

Trends in incidence and survival of upper Urinary Tract Urothelial Carcinoma (UTUC) diagnosed between 1993-2017 in the Netherlands: A study on 13,438 patients

by T. van Doeveren, M. Van Der Mark, P.J. Van Leeuwen, J.L. Boormans, K.K.H. Aben
Published 2020-07-01

An individual patient data (IPD) prognostic factor study on the value of pathological factors in clinical stage I seminoma testis patients under active surveillance from the EAU Te...

by J.L. Boormans, J. Mayor De Castro, C. Fankhauser, F. Algaba, C. Bokemeyer, K. Fizzazi, H. Gremmels, N. Nicolai, D. Nicol, J. Oldenburg, R. Sylvester, M.P. Laguna
Published 2020-07-01

Pathological T1 substaging corresponds with BCG-failure and improves the current EAU risk stratification for non-muscle invasive bladder cancer patients

by F.C. De Jong, R. Hoedemaeker, V. Kvikstad, J.T. Mensink, E.R. Boevé, D.K.E. Van Der Schoot, J.L. Boormans, E.C. Zwarthoff, T.C.M. Zuiverloon
Published 2020-07-01

Discovery of a genomic classifier for predicting clinically aggressive luminal bladder tumors with higher rates of pathological upstaging

by J.J. De Jong, Y. Liu, S.A. Boorjian, T.J. Bivalacqua, S.P. Porten, T. Wheeler, E. Davicioni, R.S. Svatek, J.L. Boormans, P.C. Black, Y. Lotan, E.A. Gibb
Published 2020-07-01

Definitions of BCG-failure (EAU) vs BCG-unresponsive (FDA) in high-risk non-muscle invasive bladder cancer: A comparison of patient outcome

by F.C. De Jong, R.F. Hoedemaeker, V. Kvikstad, J.T.M. Mensink, E.R. Boevé, D.K.E. Van Der Schoot, J.L. Boormans, E.C. Zwarthoff, T.C.M. Zuiverloon
Published 2020-07-01

PD-L1 expression does not predict BCG-failure in a large cohort of high-risk non-muscle invasive bladder cancer patients

by F.C. De Jong, R.F. Hoedemaeker, A.M. Van Der Made, V. Kvikstad, T.P.P. Van Den Bosch, E.R. Boevé, D.K.E. Van Der Schoot, J.L. Boormans, E.C. Zwarthoff, T.C.M. Zuiverloon
Published 2020-07-01

Updated follow-up from KEYNOTE-057: Phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacill...

by J.L. Boormans, R. De Wit, G.S. Kulkarni, E.M. Uchio, M. Roumiguié, L.E.M. Krieger, E.A. Singer, D.F. Bajorin, A.M. Kamat, P. Grivas, H.K. Seo, H. Nishiyama, B.R. Konethy, T. Saretsky, H. Li, K. Nam, E. Kapadia, A.V. Balar
Published 2020-07-01

Intravesical chemohyperthermia (HIVEC-E) in BCG unresponsive non-muscle invasive bladder cancer patients: Oncological outcomes of a multi-centre European registry

by W.S. Tan, F. Chiancone, P. Fedelini, J.L. Boormans, J.J. De Jong, D. Wilby, R. Robinson, M. Poggio, J. Calleja Escudero, F.J. Díaz Goizueta, A. Plata, T-A. Vögeli, A. Sousa Escandón, C. Nzeh, J.L. De La Morena, J.L. Pontones Moreno, F. Guerrero, J. Montero Torres, K. Hendricksen
Published 2020-07-01

Reduce bladder cancer recurrence in patients treated for upper urinary tract urothelial carcinoma: The REBACARE-trial

by T. van Doeveren, P.J. van Leeuwen, K.K.H. Aben, M. van der Aa, M. Barendrecht, E.R. Boevé, E.B. Cornel, A.G. van der Heijden, K. Hendricksen, W. Hirdes, A. Kooistra, B.K. Kroon, A.M. Leliveld, R.P. Meijer, H. van Melick, B. Merks, T.M. de Reijke, P. de Vries, L.F.A. Wymenga, B. Wijsman, J.L. Boormans
Published 2018-03-01